Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P78540

UPID:
ARGI2_HUMAN

ALTERNATIVE NAMES:
Arginase II; Kidney-type arginase; Non-hepatic arginase; Type II arginase

ALTERNATIVE UPACC:
P78540; B2R690; Q6FHY8

BACKGROUND:
Arginase-2, mitochondrial, identified by its alternative names such as Kidney-type arginase and Type II arginase, is integral to extra-urea cycle arginine metabolism and nitric oxide synthesis regulation. It plays a crucial role in immune response regulation, endothelial function, and cellular senescence. By modulating arginine bioavailability and RPS6KB1 signaling, Arginase-2 impacts T cell function, macrophage activation, and endothelial health, highlighting its importance in both innate and adaptive immunity.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Arginase-2 offers a pathway to novel therapeutic approaches, especially in diseases where immune dysfunction, endothelial impairment, and altered arginine metabolism are key factors. Its role in regulating immune responses and vascular health positions it as a target for innovative treatments aimed at restoring balance in these critical physiological processes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.